Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence
    • SpeciesHuman

Associated products

Specifications

Our Abpromise guarantee covers the use of ab39838 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-HtrA2 / Omi antibody (ab36854)

    Western blot

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: 0.02% Sodium Azide
    Constituents: 0.1% BSA, PBS, pH 7.2

General Info

  • Alternative names
    • High temperature requirement protein A2
    • HTRA 2
    • HtrA like serine protease
    • HtrA serine peptidase 2
    • HtrA, E. coli, homolog of, 2
    • HtrA2
    • HTRA2_HUMAN
    • mitochondrial
    • Omi stress regulated endoprotease
    • Omi stress-regulated endoprotease
    • PARK 13
    • PARK13
    • Protease serine 25
    • PRSS 25
    • PRSS25
    • Serine protease 25
    • Serine protease HTRA2
    • Serine protease HTRA2 mitochondrial
    • Serine protease htra2 mitochondrial precursor
    • Serine protease omi
    • Serine proteinase OMI
    see all
  • FunctionSerine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive.
  • Tissue specificityIsoform 1 is ubiquitous. Isoform 2 is expressed predominantly in the kidney, colon and thyroid.
  • Involvement in diseaseDefects in HTRA2 are the cause of Parkinson disease type 13 (PARK13) [MIM:610297]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
  • Sequence similaritiesBelongs to the peptidase S1B family.
    Contains 1 PDZ (DHR) domain.
  • DomainThe mature N-terminus is involved in the interaction with XIAP.
    The PDZ domain mediates interaction with MXI2.
  • Post-translational
    modifications
    Autoproteolytically activated.
  • Cellular localizationMitochondrion intermembrane space. Mitochondrion membrane. Predominantly present in the intermembrane space. Released into the cytosol following apoptotic stimuli, such as UV treatment, and stimulation of mitochondria with caspase-8 truncated BID/tBID.
  • Information by UniProt

References for Human HtrA2 / Omi peptide (ab39838)

ab39838 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab39838.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"